Altana Omnaris Adrenal Function Assessment Was "Not Ideal," FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Study design deficiences impeded Altana's attempt to distinguish Omnaris (ciclesonide) from other nasal corticosteroids as having less potential to suppress the cortisol system and adrenal function